GEN 1053
Alternative Names: BNT-313; GEN-1053Latest Information Update: 17 Jun 2024
At a glance
- Originator Genmab
- Developer BioNTech; Genmab
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 07 Jun 2024 Genmab in collaboration with BioNTech terminates a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) (IV, Infusion), due to strategic evaluation of GEN 1053 in the context of Genmab's portfolio (NCT05435339)
- 29 Aug 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in Spain, USA (IV) (NCT05435339)
- 08 Aug 2022 9365018: incorporated QC feedback